These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26933891)

  • 1. Recent advances in the identification of Tat-mediated transactivation inhibitors: progressing toward a functional cure of HIV.
    Tabarrini O; Desantis J; Massari S
    Future Med Chem; 2016; 8(4):421-42. PubMed ID: 26933891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription.
    Mousseau G; Clementz MA; Bakeman WN; Nagarsheth N; Cameron M; Shi J; Baran P; Fromentin R; Chomont N; Valente ST
    Cell Host Microbe; 2012 Jul; 12(1):97-108. PubMed ID: 22817991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37.
    Okamoto H; Cujec TP; Okamoto M; Peterlin BM; Baba M; Okamoto T
    Virology; 2000 Jul; 272(2):402-8. PubMed ID: 10873784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Host Factors on the Regulation of Tat-Mediated HIV-1 Transcription.
    Mousseau G; Valente ST
    Curr Pharm Des; 2017; 23(28):4079-4090. PubMed ID: 28641539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tat-Based Therapies as an Adjuvant for an HIV-1 Functional Cure.
    Jin H; Li D; Lin MH; Li L; Harrich D
    Viruses; 2020 Apr; 12(4):. PubMed ID: 32276443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probabilistic control of HIV latency and transactivation by the Tat gene circuit.
    Cao Y; Lei X; Ribeiro RM; Perelson AS; Liang J
    Proc Natl Acad Sci U S A; 2018 Dec; 115(49):12453-12458. PubMed ID: 30455316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Didehydro-Cortistatin A: a new player in HIV-therapy?
    Mousseau G; Valente ST
    Expert Rev Anti Infect Ther; 2016; 14(2):145-8. PubMed ID: 26581953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of tat-mediated HIV-1-LTR transactivation and virus replication by sulfhydryl compounds with chelating properties.
    Demirhan I; Chandra A; Sarin PS; Hasselmayer O; Hofmann D; Chandra P
    Anticancer Res; 2000; 20(4):2513-7. PubMed ID: 10953320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 6-desfluoroquinolones as HIV-1 Tat-mediated transcription inhibitors.
    Tabarrini O; Massari S; Cecchetti V
    Future Med Chem; 2010 Jul; 2(7):1161-80. PubMed ID: 21426162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to the Tat Inhibitor Didehydro-Cortistatin A Is Mediated by Heightened Basal HIV-1 Transcription.
    Mousseau G; Aneja R; Clementz MA; Mediouni S; Lima NS; Haregot A; Kessing CF; Jablonski JA; Thenin-Houssier S; Nagarsheth N; Trautmann L; Valente ST
    mBio; 2019 Jul; 10(4):. PubMed ID: 31266880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting HIV transcription: the quest for a functional cure.
    Mousseau G; Mediouni S; Valente ST
    Curr Top Microbiol Immunol; 2015; 389():121-45. PubMed ID: 25731772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-viral opportunities during transcriptional activation of latent HIV in the host chromatin.
    Mujtaba S; Zhou MM
    Methods; 2011 Jan; 53(1):97-101. PubMed ID: 20828615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel neuroprotective GSK-3β inhibitor restricts Tat-mediated HIV-1 replication.
    Guendel I; Iordanskiy S; Van Duyne R; Kehn-Hall K; Saifuddin M; Das R; Jaworski E; Sampey GC; Senina S; Shultz L; Narayanan A; Chen H; Lepene B; Zeng C; Kashanchi F
    J Virol; 2014 Jan; 88(2):1189-208. PubMed ID: 24227837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in Targeting the HIV-1 Tat/TAR Complex.
    Abulwerdi FA; Le Grice SFJ
    Curr Pharm Des; 2017; 23(28):4112-4121. PubMed ID: 28625133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV latency reversing agents act through Tat post translational modifications.
    Khoury G; Mota TM; Li S; Tumpach C; Lee MY; Jacobson J; Harty L; Anderson JL; Lewin SR; Purcell DFJ
    Retrovirology; 2018 May; 15(1):36. PubMed ID: 29751762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a "Block-and-Lock" Strategy for HIV-1 Treatment.
    Kessing CF; Nixon CC; Li C; Tsai P; Takata H; Mousseau G; Ho PT; Honeycutt JB; Fallahi M; Trautmann L; Garcia JV; Valente ST
    Cell Rep; 2017 Oct; 21(3):600-611. PubMed ID: 29045830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of protein-RNA complexation that target the RNA: specific recognition of human immunodeficiency virus type 1 TAR RNA by small organic molecules.
    Mei HY; Cui M; Heldsinger A; Lemrow SM; Loo JA; Sannes-Lowery KA; Sharmeen L; Czarnik AW
    Biochemistry; 1998 Oct; 37(40):14204-12. PubMed ID: 9760258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nrf2 is involved in inhibiting Tat-induced HIV-1 long terminal repeat transactivation.
    Zhang HS; Li HY; Zhou Y; Wu MR; Zhou HS
    Free Radic Biol Med; 2009 Aug; 47(3):261-8. PubMed ID: 19409485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Didehydro-Cortistatin A Inhibits HIV-1 by Specifically Binding to the Unstructured Basic Region of Tat.
    Mediouni S; Chinthalapudi K; Ekka MK; Usui I; Jablonski JA; Clementz MA; Mousseau G; Nowak J; Macherla VR; Beverage JN; Esquenazi E; Baran P; de Vera IMS; Kojetin D; Loret EP; Nettles K; Maiti S; Izard T; Valente ST
    mBio; 2019 Feb; 10(1):. PubMed ID: 30723126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional control of HIV replication by multiple modulators and their implication for a novel antiviral therapy.
    Victoriano AF; Okamoto T
    AIDS Res Hum Retroviruses; 2012 Feb; 28(2):125-38. PubMed ID: 22077140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.